Kendall Capital Partners

Bilayer Therapeutics is a development-stage company founded in 2020. It is developing treatments for metabolic and motility disorders using chenodeoxycholate delivered through proprietary bilayer tablet technology.

Centivax uses a computational immune-engineering platform to develop vaccines and therapies targeting diverse classes of threats. Its influenza candidate is followed by programs for RSV/hMPV and herpesviruses.

EpiBone uses stem cells to create bone and cartilage implants for trauma and degenerative conditions. Founded in 2014 with technology from MIT and Columbia, the company completed a first-in-human clinical trial.

General Fluidics aims to provide blood diagnostics that are accurate, reliable, and accessible.

The FDA draft guidance describes ways to conduct randomized controlled trials in routine clinical settings using data collected during medical visits and focusing on essential data collection.

Honoring Mr. Ratan Tata: Visionary Investor, Compassionate Industrialist, Champion for a Better World, and former Chairman of Tata Trusts – invested in one of the portfolio companies of Kendall Capital Partners.

Inflation Reduction Act: Pharma’s New Landscape

Increasing Healthspan, Extending Lifespan

Giovanni Traverso directs the Laboratory for Translational Engineering at MIT and Harvard and holds positions at MIT, Brigham and Women’s Hospital, Harvard Medical School, and the Broad Institute. He received degrees from Cambridge and a PhD from Johns Hopkins.

Kaushal Solanki is the founder and CEO of Eyenuk, an AI digital health company focused on automated medical imaging, including eye health.

The CEO of EpiBone, Dr. Nina Tandon, reflects on her journey from engineer to entrepreneur, blending science and strategy to reshape healthcare.

Eyenuk, Inc. is an FDA cleared, global artificial intelligence (AI) digital health company

Investing in Breakthroughs that Redefine Health at Scale